|
Research and Markets: Roche/Genentech/Novartis' Asthma Treatment – Xolair …
Business Wire (press release) Roche/Genentech/Novartis' Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI. Research and Markets: Merck's Dulera Asthma Treatment – Forecast and Market … |
View full post on asthma – Google News